Background: The European Food Information Resource (EuroFIR) network has established the eBASIS (Bioactive Substances in Food Information System) online food composition and biological effects database for plant-derived bioactive compounds (phytochemicals). On the basis of submitted evidence, the European Food Safety Authority (EFSA) expert panel on Dietetic Products, Nutrition and Allergies assesses whether claims made under articles 13.1, 13.5 or 14 of the Regulation (EC) 1924/ 2006, which governs the use of nutrition and health claims on foods, are scientifically justified. This report evaluates the eBASIS biological effects database in the preparation and evaluation of health claims dossiers. Methods: The eBASIS biological effects database is a compilation of expert-evaluated data extracted from the literature, prioritising human intervention studies to investigate health effects of phytochemicals. Currently included are 4750 records from 445 studies providing data on 56 validated biomarkers, mainly relating to cardio-metabolic and bone health outcomes. The data cover 144 bioactive compounds from 17 compound classes. Using the EFSA Register of Questions and the database of general function health claims, we identified claims relating to phytochemicals made under articles 13.1, 13.5 and 14 and compared them with the eBASIS database to identify overlap between them. Results: The EFSA online health claims database contains 4240 submissions under article 13.1, of which 2157 pertain to plants or plant-based bioactive compounds; 496 of these relate to plants or bioactive compounds included in the eBASIS biological effects database. Out of the 18 current 13.5 'new function' claims on EFSA's register of questions, 7 are for plants or plant-based bioactive compounds, of which 6 are included in eBASIS. Of the 222 defined article 14 claims, 21 pertain to plants or plant-based bioactive compounds, of which 19 are in eBASIS. Conclusions: There is extensive overlap between eBASIS and the submitted health claims that relate to plant-based bioactive compounds. EuroFIR eBASIS is a useful tool for regulators to independently check completeness of health claims applications relating to phytochemicals and is a potentially valuable resource to assist claimants in the compilation of dossiers on functional foods and health claims.
directly to the complex in vivo situation was overly simplistic and it is now accepted that more subtle mechanisms, such as stimulation of endogenous antioxidant capacity and modulation of inflammatory processes, might be implicated (Williamson and Holst, 2008) . In animal models and in vitro systems, polyphenols, for instance, not only trap and scavenge free radicals but they also regulate nitric oxide, induce apoptosis, inhibit cell proliferation and angiogenesis and exhibit phytoestrogenic activity (Arts and Hollman, 2005) . Although relatively scarce until recently, data from randomised controlled trials are starting to proliferate as the literature in this field matures and epidemiologically derived hypotheses are explored in an experimental setting. For example, in a recent meta-analysis, Hooper et al. (2008) reported clinically relevant improvements in cardiovascular disease risk markers, including blood pressure, lipoproteins and flow-mediated dilatation in response to intervention with flavonoids or flavonoid-rich foods. Data that confirm or refute evidence of a beneficial effect of phytochemicals have direct relevance on public health promotion and disease prevention, and are of great interest to the food industry, as the identification and incorporation of food-derived constituents with proven beneficial health effects (also known as nutraceuticals) has led to the development of the functional food concept, which encompasses fresh or processed food with health-promoting and/or disease-preventing properties (Schwager et al., 2008) .
EuroFIR eBASIS
The European Food Information Resource (EuroFIR) Network of Excellence has established EuroFIR eBASIS (BioActive Substances in Foods Information System), which is an online database that uniquely combines food composition and biological effects data for plant-based bioactive compounds, hosted at http://www.polytec.dk/ebasis. Information on accessing the database is provided on the homepage. The EuroFIR eBASIS resource is a compilation of critically evaluated data extracted from peer-reviewed literature and consists of two compatible databases covering extensive food composition data and biological effects data for phytochemicals, as well as an up-to-date list of the major food plants consumed in Europe. The database includes data on approximately 200 plant-based bioactive compounds, covering major compound classes: anthocyanins, capsaicinoids, carotenoids (excluding b-carotene), coumestans, cysteine sulphoxides, flavanols, flavanones, flavones, flavonols, glucosinolates, isoflavones, lignans, polyacetylenes, stilbenes, proanthocyanidins and phytosterols. Selection of compound classes was based on the current state of knowledge of the biological activities of the compounds in these classes, which might contribute to a net health benefit from ingestion of foods rich in these compounds. In addition, the EuroFIR eBASIS database contains critically evaluated compositional and biological data on bioactive compounds with putative toxic effects. A comprehensive introduction to the EuroFIR eBASIS project, including the scientific team, scope of the database, its design and construction, data extraction and evaluation, quality assessment, quality assurance and reporting capabilities, was published by Gry et al. (2007) .
EuroFIR eBASIS contains data on approximately 550 plants commonly consumed in Europe. Resources used to compile the plant list include World Economic Plants (Wiersema and Leon, 1999) For each plant, information may be printed as a succinct report, including the composition of bioactive constituents. Data in eBASIS on food composition and biological effects are linked back to the plant list; wherever plant information was provided in the original literature source, these data were captured and integrated reports generated on individual plants, drawing data from the plant list and from the food composition and biological effects databases.
Food composition data included in EuroFIR eBASIS are extracted from primary research published in peer-reviewed journals by a panel of 12 evaluators with expertise in specific compound classes. Literature searches are conducted in three online databases-CabWeb (CAB Partnership, 2003 -2005 ; http://www.cabweb.net), ISI Web of Knowledge (http://portal.isiknowledge.com/portal.cgi) and CAS SciFinder (http://www.cas.org/scifinder/scicover2.html), and articles containing potentially valuable analytical data on bioactive constituents in human foods are retrieved. As detailed in Gry et al. (2007) , the abstracts are reviewed by evaluators who are expert in the compound classes to which they are assigned, and articles containing potentially valuable quantitative data on bioactive constituents in human foods are retrieved.
The focus of the current report is to evaluate the biological effects data. Literature on beneficial effects of plant-based bioactive compounds, including in vitro, animal and human studies, is extracted from PubMed (http://www.ncbi.nlm.
nih.gov/sites/entrez?db ¼ pubmed) and from the ISI Web of Knowledge (http://www.ars-grin.gov). For compound classes with a large body of literature available, a panel of expert scientists in nutrition, phytochemicals research and food safety prioritise articles for inclusion on the basis of specific criteria: human intervention studies are prioritised over studies carried out using animal and in vitro model systems, with the exception of studies that have carcinogenicity as an end point; priority health outcomes are cardiovascular health, obesity, metabolic health (that is, insulin resistance syndrome), type II diabetes, cancer and bone health; and papers that describe effects in well-characterised and pure compounds are prioritised over studies using mixtures of compounds. All searches are fully documented, together with the total number of references that may contain data suitable for entry into the database. The expert evaluators are responsible for extracting the data and submitting it to the database in a standardised online input form, capturing relevant information from the study, including plant and/or compound information, experimental design and results. Evaluators are also required to assess the quality of each study using objective criteria: six aspects of the study are examined in detail-study design, subjects, characterisation of material studied, conduct of study, methodology, including statistical approaches and resultsand a score of 1-5 is allocated for each. On the basis of these scores, the study is assigned an overall quality code: Aacceptable; B-study with some limitations; C-study with serious limitations.
The database currently contains over 750 records of experimental data from 445 studies examining beneficial effects of plant-based bioactive compounds. The database includes 144 bioactive compounds from 17 compound classes and 68 food plants. Experimental data on 56 biomarkers are currently available, mainly related to cardiovascular disease risk modification and osteoporosis, including lipoprotein profiles, blood pressure, homocysteine metabolism, haemostatic function, glucose, fat and protein metabolism, antioxidant status, inflammatory and immune markers, endocrine function and biomarkers of bone metabolism and bone density. As the database is constructed from the published literature, estimates of coverage account for the volume of potential data, given that papers often cover multiple compounds, plants and health effects, producing a much greater yield than the title or abstract might suggest. On this basis, current (March 2010) estimates of coverage for the 17 compound classes range from 50% (cysteine sulphoxides, flavanols) to 75% (isoflavones, carotenoids (excluding b-carotene)) to 100% (glucosinolates, and some of the lesser compounds such as coumestans). EuroFIR eBASIS will continue to expand as data from additional studies are submitted and approved for inclusion, pending resources.
The database contains a sophisticated data retrieval system, allowing users to search for specific information to suit their requirements. Searches can be limited by plant, compound, compound class, study type, biomarker and quality, or any combination of these. The user then selects the information to be viewed in the report. For example, a simple report searching for effects of a specific compound in human studies may include plant source, treatment duration, dose, experimental outcome and quality code. Each report contains a number of links, including a link to the original input form submitted by the evaluator, giving full details of the study, a link to the original abstract or full text article (if their institutional access allows) and a link to detailed plant information. All reports are immediately downloadable as a spreadsheet, enabling the user to manage the data as required.
Health claims regulation
To ensure that claims about the health benefits of foods and food constituents are accurate and not misleading to consumers, the European Commission adopted a regulation on the use of nutrition and health claims in To use a health claim in food labelling or marketing, a food business operator must apply for authorisation: all claims are subject to assessment by the European Food Safety Authority (EFSA) on the basis of the strength of scientific evidence accompanying the health claim application. A list of potential article 13.1 claims (general function claims based on generally accepted scientific evidence) was required to be submitted by food business operators to their Member State authority by January 2008. Successful claims will be included in the community register of nutrition and health claims, which will be made available for manufacturers to use throughout the European Union, with the exception of health claims based on proprietary data. Health claims relating to general function claims based on newly developed scientific evidence (article 13.5 claims) and health claims referring to reduction of disease risk or to children's development and health (article 14 claims) must go through an authorisation process on a case-by-case basis. Food business operators must compile a dossier containing full details of the food/constituent and substantial scientific evidence verifying the claim. Dossiers to support article 14 claims must be prepared according to the EFSA technical guidance for applicants (European Food Safety Authority, 2007) . Data from human studies, addressing the relationship between the food/constituent and health effect, are mandatory and a systematic, transparent and comprehensive review of human studies data is required. Data from animal and in vitro studies may only be included as supporting evidence.
Comparison of EuroFIR eBASIS to health claims evaluations-proof of concept
There is a rapidly growing trend to incorporate plant-derived bioactive compounds with putative beneficial effects in functional food products, which has resulted in widespread use of health claims in food labelling and advertising. With respect to the Regulation, many health claims involving nonnutritive bioactive compounds fall under articles 13.1, 13.5 and 14. Given that EuroFIR eBASIS includes scientific data on a wide range of plants and plant-based bioactive compounds, we evaluated the overlap between the EuroFIR eBASIS biological effects database and health claims submitted to EFSA.
The EFSA database of applications for article 13.1 'general function' health claims (submitted for evaluation) is available online (http://www.efsa.europa.eu/en/ndaclaims/ ndaclaims13.htm). Of the 4240 proposed claims, 2157 were found to relate to plants or plant-based bioactive compounds, and 496 of these relate to plants or bioactive compounds for which data are included in the eBASIS biological effects database. Health claims relating to plantbased components other than non-nutritive bioactive compounds, for example, fibre derived from oats, were not included in the count. A further search was conducted in the EFSA's Register of Questions to identify relevant article 13.5 and 14 claims. A total of 18 claims were registered under article 13.5 (excluding withdrawn and undefined applications): seven of these were for plants or plant-based bioactive compounds, six of which were for plants or compounds for which data are included in the biological effects database. With respect to article 14, a total of 222 claims were registered (excluding withdrawn and undefined applications): 21 of these related to plants or plant-based bioactive compounds, 19 of which were for plants or compounds for which data are included in the biological effects database. Table 1 shows the article 13.5 and article 14 health claim applications received by EFSA compared with data included in the eBASIS biological effects database. The comparisons undertaken indicate an overlap between EuroFIR eBASIS and the health claims submitted to EFSA. The eBASIS biological effects database contains data on plants or bioactive compounds that relate to 11% of the total number of article 13.1, 33% of article 13.5 and 8% of article 14 claims. Approximately 50% of the total number of article 13.1, 39% of article 13.5 and 9% of article 14 claims relate to plantbased bioactive compounds, and of these, a substantial proportion is included in the EuroFIR eBASIS biological effects database (23% of article 13.1, 86% of article 13.5 and 90% of article 14 bioactive claims).
Application of EuroFIR eBASIS to health claims evaluations-proof of principle
A number of article 14 health claim applications, listed in the EFSA Register of Questions, relate to plant sterols and blood cholesterol: specifically 'plant sterols lower blood cholesterol'. The following example demonstrates how EuroFIR eBASIS could be used to compile a scientific dossier to substantiate a health claim that 'plant sterols lower blood cholesterol'.
A search was conducted in the eBASIS biological effects database using the following terms: phytosterols, human studies, total and low-density lipoprotein cholesterol. A total of 37 records were retrieved using these criteria. The following fields were selected for output in the report: reference details, compound, experimental design, concentration, treatment duration and experimental outcome. All 37 human intervention study records found a reduction in total or low-density lipoprotein cholesterol, or cholesterol absorption, after administration of phytosterols or phytostanols. The extent of reduction of total cholesterol ranged from 4 to 11.9%, whereas low-density lipoproteincholesterol reduction ranged from 5 to 26.8%, with daily doses of phytosterols/stanols ranging from 0.3 to 4 g. The foods or constituents tested included products enriched with phytosterols/stanols-such as margarine, milk, yoghurt and orange juice-and phytosterol/stanol-containing capsules. Table 2 shows an abbreviated report from the biological effects database summarising the literature in the database on the effect of phytosterols/stanols on cholesterol in human intervention studies. Text boxes have been summarised for the purpose of illustration in this publication. This type of report takes about 10 min to generate and offers the user concise information about the studies, with the option of accessing further information through a link to the original input form submitted to the database, or through a link to the abstract or full text PDF of the original publication, depending on the user's access to the journal.
Discussion
Of the health claims currently registered with EFSA that relate to plant-based bioactive constituents, relevant information on about one-quarter of article 13.1 and up to 90% of article 13.5 and 14 claims are included in the EuroFIR eBASIS biological effects database. A number of claims relating to dairy products, particularly milk peptides, have also been submitted to EFSA. Bioactive compounds from animal products are receiving increased attention from researchers and the evidence to support the use of such peptides as functional ingredients in foods is growing. The possibility of including animal-derived bioactives in EuroFIR eBASIS is currently being reviewed. Currently, EuroFIR eBASIS includes a list of 550 food plants consumed in Europe. One limitation of the database is that it does not currently include plants used as medicinal herbs. A number of health claims submitted to EFSA relate to medicinal herbs, such as Silybum marianum (milk thistle) and Hypericum perforatum (St John's wort). Although these herbs are not currently included in EuroFIR eBASIS, there are plans to expand the database to include these plants in the near future.
In conclusion, the comparison between the health claims submitted to EFSA and the evidence collated in EuroFIR eBASIS suggests that the database provides a useful resource for both the evaluation of health claim applications on plantbased bioactive compounds and the preparation of scientific dossiers to accompany health claims. It is likely that further claims on plant-based bioactive compounds will be submitted to EFSA as research continues to expand in this area.
